stockrowBiogen Inc.
BIIB Healthcare Drug Manufacturers General
Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024.
- Revenue
- +10.6%
- EPS
- −104.4%
- Free cash flow
- −69.3%
- Total debt
- +16.0%
Quarter to September 2026, against a year earlier
Follow BIIB
Alert me
Biogen Inc. (BIIB) Return on invested capital
Biogen Inc.'s return on invested capital over the twelve months to 30 September 2026 was 1.94%, down 3.7 percentage points from fiscal 2025 (5.61%). Over the past ten years it has ranged from 4.91% (fiscal 2023) to 33.0% (fiscal 2019); the current reading is higher than 18% of that period. That is below the Drug Manufacturers General industry median of 6.26% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 5.61% | (1.83) |
| FY2024 | 7.44% | 2.53 |
| FY2023 | 4.91% | (9.82) |
| FY2022 | 14.7% | 1.51 |
| FY2021 | 13.2% | (7.13) |
| FY2020 | 20.4% | (12.69) |
| FY2019 | 33.0% | 9.19 |
| FY2018 | 23.9% | 1.34 |
| FY2017 | 22.5% | (0.91) |
| FY2016 | 23.4% | (1.10) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| NVO Novo Nordisk A/S compare | 28.7% |
| AMGN Amgen Inc. compare | 14.3% |
| BMY Bristol Myers Squibb Company compare | 13.2% |
| AZN AstraZeneca PLC compare | 12.3% |
| GSK GSK PLC Sponsored ADR compare | 9.61% |
| SNY Sanofi compare | 7.05% |
| PFE Pfizer Inc. compare | 6.19% |
| BIIB Biogen Inc. | 1.94% |
| GILD Gilead Sciences, Inc. compare | −4.51% |
| Drug Manufacturers General industry median | 6.26% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on BIIB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement